M Elizabeth Halloran

List of Publications by Year
in descending order

103 papers	11,268 citations	109137 35 h-index	38300 95 g-index
115 all docs	115 docs citations	115 times ranked	14781 citing authors

#	Article	IF	Citations
1	Inverse probability weighted estimators of vaccine effects accommodating partial interference and censoring. Biometrics, 2022, 78, 777-788.	0.8	3
2	Discussion on â€œEstimating vaccine efficacy over time after a randomized study is unblindedâ€• by Anastasios A. Tsiatis and Marie Davidian. Biometrics, 2022, 78, 839-840.	0.8	2
3	Protecting the herd with vaccination. Science, 2022, 375, 1088-1089.	6.0	6
4	Quantifying the importance and location of SARS-CoV-2 transmission events in large metropolitan areas. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	35
5	Estimates of Inactivated Influenza Vaccine Effectiveness Among Children in Senegal: Results From 2 Consecutive Cluster-Randomized Controlled Trials in 2010 and 2011. Clinical Infectious Diseases, 2021, 72, e959-e969.	2.9	6
6	Cost-effectiveness of live-attenuated influenza vaccination among school-age children. Vaccine, 2021, 39, 447-456.	1.7	4
7	Inferring high-resolution human mixing patterns for disease modeling. Nature Communications, 2021, 12, 323.	5.8	161
8	Improving adolescent human papillomavirus (HPV) immunization uptake in school-based health centers through awareness campaigns. Vaccine, 2021, 39, 1765-1772.	1.7	4
9	Estimating population-level effects of the acellular pertussis vaccine using routinely collected immunization data. Clinical Infectious Diseases, 2021, 73, 2101-2107.	2.9	1
10	Comment on AIDS and COVIDâ€19: A tale of two pandemics and the role of statisticians. Statistics in Medicine, 2021, 40, 2524-2525.	0.8	2
11	Using simulated infectious disease outbreaks to inform site selection and sample size for individually randomized vaccine trials during an ongoing epidemic. Clinical Trials, 2021, 18, 630-638.	0.7	3
12	Disseminated Effects in Agent-Based Models: A Potential Outcomes Framework and Application to Inform Preexposure Prophylaxis Coverage Levels for HIV Prevention. American Journal of Epidemiology, 2021, 190, 939-948.	1.6	12
13	Cryptic transmission of SARS-CoV-2 and the first COVID-19 wave. Nature, 2021, 600, 127-132.	13.7	61
14	Dengue and Zika virus infections in children elicit cross-reactive protective and enhancing antibodies that persist long term. Science Translational Medicine, 2021, 13, eabg9478.	5.8	32
15	Challenges of evaluating and modelling vaccination in emerging infectious diseases. Epidemics, 2021, 37, 100506.	1.5	14
16	Successes and Failures of the Live-attenuated Influenza Vaccine: Can We Do Better?. Clinical Infectious Diseases, 2020, 70, 1029-1037.	2.9	12
17	Reply to Lindsey, HÃ¶schler, and de Silva. Clinical Infectious Diseases, 2020, 70, 2236-2237.	2.9	0
18	The TIRS trial: protocol for a cluster randomized controlled trial assessing the efficacy of preventive targeted indoor residual spraying to reduce Aedes-borne viral illnesses in Merida, Mexico. Trials, 2020, 21, 839.	0.7	16

#	Article	IF	Citations
19	Ensemble forecast modeling for the design of COVID-19 vaccine efficacy trials. Vaccine, 2020, 38, 7213-7216.	1.7	32
20	Validity of university studentsâ€™ self-reported vaccination status after a meningococcal B outbreak. Journal of American College Health, 2020, , 1-6.	0.8	2
21	Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions. Annals of Internal Medicine, 2020, 173, 576-577.	2.0	3
22	Modelling the impact of testing, contact tracing and household quarantine on second waves of COVID-19. Nature Human Behaviour, 2020, 4, 964-971.	6.2	605
23	Achieving coordinated national immunity and cholera elimination in Haiti through vaccination: a modelling study. The Lancet Global Health, 2020, 8, e1081-e1089.	2.9	26
24	Zika virus infection enhances future risk of severe dengue disease. Science, 2020, 369, 1123-1128.	6.0	171
25	Estimands and inference in clusterâ€randomized vaccine trials. Pharmaceutical Statistics, 2020, 19, 710-719.	0.7	5
26	The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science, 2020, 368, 395-400.	6.0	2,784
27	Aggregated mobility data could help fight COVID-19. Science, 2020, 368, 145-146.	6.0	303
28	Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks. New England Journal of Medicine, 2020, 382, 1366-1369.	13.9	63
29	Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study. Lancet Infectious Diseases, The, 2020, 20, 793-802.	4.6	541
30	Designing effective control of dengue with combined interventions. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3319-3325.	3.3	29
31	Estimating the cost of illness and burden of disease associated with the 2014â€“2015 chikungunya outbreak in the U.S. Virgin Islands. PLoS Neglected Tropical Diseases, 2019, 13, e0007563.	1.3	28
32	Design of vaccine efficacy trials during public health emergencies. Science Translational Medicine, 2019, 11, .	5.8	41
33	Genomic epidemiology supports multiple introductions and cryptic transmission of Zika virus in Colombia. BMC Infectious Diseases, 2019, 19, 963.	1.3	12
34	Reply to Skowronski and De Serres. Clinical Infectious Diseases, 2019, 69, 2231-2232.	2.9	1
35	Effectiveness of Seasonal Influenza Vaccination in Children in Senegal During a Year of Vaccine Mismatch: A Cluster-randomized Trial. Clinical Infectious Diseases, 2019, 69, 1780-1788.	2.9	15
36	Effects of infection history on dengue virus infection and pathogenicity. Nature Communications, 2019, 10, 1246.	5.8	26

#	Article	IF	Citations
37	Impact of Rotavirus Vaccine Introduction in Children Less Than 2 Years of Age Presenting for Medical Care With Diarrhea in Rural Matlab, Bangladesh. Clinical Infectious Diseases, 2019, 69, 2059-2070.	2.9	8
38	Optimizing and evaluating biomarker combinations as trialâ€level general surrogates. Statistics in Medicine, 2019, 38, 1135-1146.	0.8	3
39	Reply to Aguiar and Stollenwerk. Clinical Infectious Diseases, 2018, 66, 642-642.	2.9	2
40	Estimating population effects of vaccination using large, routinely collected data. Statistics in Medicine, 2018, 37, 294-301.	0.8	11
41	Dependency of Vaccine Efficacy on Preexposure and Age: A Closer Look at a Tetravalent Dengue Vaccine. Clinical Infectious Diseases, 2018, 66, 178-184.	2.9	28
42	Meningococcal carriage within households in the African meningitis belt: A longitudinal pilot study. Journal of Infection, 2018, 76, 140-148.	1.7	17
43	Seroprevalence of Dengue Antibodies in Three Urban Settings in Yucatan, Mexico. American Journal of Tropical Medicine and Hygiene, 2018, 98, 1202-1208.	0.6	14
44	Quantifying the risk of local Zika virus transmission in the contiguous US during the 2015â€“2016 ZIKV epidemic. BMC Medicine, 2018, 16, 195.	2.3	11
45	Dengue seroprevalence in a cohort of schoolchildren and their siblings in Yucatan, Mexico (2015-2016). PLoS Neglected Tropical Diseases, 2018, 12, e0006748.	1.3	9
46	Epidemiology of dengue and other arboviruses in a cohort of school children and their families in Yucatan, Mexico: Baseline and first year follow-up. PLoS Neglected Tropical Diseases, 2018, 12, e0006847.	1.3	22
47	Design of vaccine trials during outbreaks with and without a delayed vaccination comparator. Annals of Applied Statistics, 2018, 12, 330-347.	0.5	6
48	Forecasting the effectiveness of indoor residual spraying for reducing dengue burden. PLoS Neglected Tropical Diseases, 2018, 12, e0006570.	1.3	44
49	Evaluation and comparison of predictive individual-level general surrogates. Biostatistics, 2018, 19, 307-324.	0.9	0
50	Intermediate levels of vaccination coverage may minimize seasonal influenza outbreaks. PLoS ONE, 2018, 13, e0199674.	1.1	8
51	Efficacy of a bivalent killed whole-cell cholera vaccine over five years: a re-analysis of a cluster-randomized trial. BMC Infectious Diseases, 2018, 18, 84.	1.3	9
52	An Assessment of Household and Individual-Level Mosquito Prevention Methods during the Chikungunya Virus Outbreak in the United States Virgin Islands, 2014â€“2015. American Journal of Tropical Medicine and Hygiene, 2018, 98, 845-848.	0.6	4
53	Comment on Laber et al. Journal of the Royal Statistical Society Series C: Applied Statistics, 2018, 67, 776.	0.5	0
54	Rotavirus vaccine effectiveness in low-income settings: An evaluation of the test-negative design. Vaccine, 2017, 35, 184-190.	1.7	37

#	Article	IF	Citations
55	Spread of Zika virus in the Americas. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4334-E4343.	3.3	249
56	Zika virus evolution and spread in the Americas. Nature, 2017, 546, 411-415.	13.7	323
57	Antibody-dependent enhancement of severe dengue disease in humans. Science, 2017, 358, 929-932.	6.0	800
58	Immune correlates of protection for dengue: State of the art and research agenda. Vaccine, 2017, 35, 4659-4669.	1.7	81
59	Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: A cluster-randomized trial. PLoS Medicine, 2017, 14, e1002282.	3.9	46
60	Simulations for designing and interpreting intervention trials in infectious diseases. BMC Medicine, 2017, 15, 223.	2.3	64
61	Molecular Infectious Disease Epidemiology: Survival Analysis and Algorithms Linking Phylogenies to Transmission Trees. PLoS Computational Biology, 2016, 12, e1004869.	1.5	36
62	Containing Ebola at the Source with Ring Vaccination. PLoS Neglected Tropical Diseases, 2016, 10, e0005093.	1.3	54
63	Comparing Biomarkers as Trial Level General Surrogates. Biometrics, 2016, 72, 1046-1054.	0.8	9
64	Dependent Happenings: a Recent Methodological Review. Current Epidemiology Reports, 2016, 3, 297-305.	1.1	48
65	A Bayesian approach to estimating causal vaccine effects on binary postâ€infection outcomes. Statistics in Medicine, 2016, 35, 53-64.	0.8	1
66	The First Reported Outbreak of Chikungunya in the U.S. Virgin Islands, 2014â€“2015. American Journal of Tropical Medicine and Hygiene, 2016, 95, 885-889.	0.6	30
67	Spatiotemporal dynamics of the Ebola epidemic in Guinea and implications for vaccination and disease elimination: a computational modeling analysis. BMC Medicine, 2016, 14, 130.	2.3	30
68	Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies. Vaccine, 2016, 34, 3796-3802.	1.7	4
69	Transmission dynamics of Ebola virus disease and intervention effectiveness in Sierra Leone. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4488-4493.	3.3	70
70	Projected Impact of Dengue Vaccination in YucatÃ¡n, Mexico. PLoS Neglected Tropical Diseases, 2016, 10, e0004661.	1.3	44
71	One versus two doses: What is the best use of vaccine in an influenza pandemic?. Epidemics, 2015, 13, 17-27.	1.5	22
72	The dengue vaccine pipeline: Implications for the future of dengue control. Vaccine, 2015, 33, 3293-3298.	1.7	109

#	Article	IF	Citations
73	Spatiotemporal spread of the 2014 outbreak of Ebola virus disease in Liberia and the effectiveness of non-pharmaceutical interventions: a computational modelling analysis. Lancet Infectious Diseases, The, 2015, 15, 204-211.	4.6	226
74	The case for a typhoid vaccine probe study and overview of design elements. Vaccine, 2015, 33, C30-C35.	1.7	3
75	Ebola and beyond. Science, 2015, 348, 46-48.	6.0	18
76	School-Located Influenza Vaccination Reduces Community Risk for Influenza and Influenza-Like Illness Emergency Care Visits. PLoS ONE, 2014, 9, e114479.	1.1	25
77	Household Transmission of Vibrio cholerae in Bangladesh. PLoS Neglected Tropical Diseases, 2014, 8, e3314.	1.3	45
78	Comparative Effectiveness of Different Strategies of Oral Cholera Vaccination in Bangladesh: A Modeling Study. PLoS Neglected Tropical Diseases, 2014, 8, e3343.	1.3	24
79	Assessing effects of cholera vaccination in the presence of interference. Biometrics, 2014, 70, 731-741.	0.8	50
80	Assessing the International Spreading Risk Associated with the 2014 West African Ebola Outbreak. PLOS Currents, 2014, 6, .	1.4	251
81	Emerging, evolving, and established infectious diseases and interventions. Science, 2014, 345, 1292-1294.	6.0	18
82	Interference and Sensitivity Analysis. Statistical Science, 2014, 29, 687-706.	1.6	37
83	Estimating Strainâ€Specific and Overall Efficacy of Polyvalent Vaccines Against Recurrent Pathogens From a Crossâ€Sectional Study. Biometrics, 2013, 69, 235-244.	0.8	17
84	Causal Inference for Vaccine Effects on Infectiousness. International Journal of Biostatistics, 2012, 8, 1-40.	0.4	21
85	Design and Analysis of Vaccine Studies. Statistics in the Health Sciences, 2010, , .	0.2	189
86	Toward Causal Inference With Interference. Journal of the American Statistical Association, 2008, 103, 832-842.	1.8	456
87	Containing Pandemic Influenza at the Source. Science, 2005, 309, 1083-1087.	6.0	1,044
88	Estimating Vaccine Efficacy From Secondary Attack Rates. Journal of the American Statistical Association, 2003, 98, 38-46.	1.8	35
89	Estimating Efficacy of Trivalent, Cold-adapted, Influenza Virus Vaccine (CAIV-T) against Influenza A (H1N1) and B Using Surveillance Cultures. American Journal of Epidemiology, 2003, 158, 305-311.	1.6	72
90	Containing Bioterrorist Smallpox. Science, 2002, 298, 1428-1432.	6.0	324

#	Article	IF	Citations
91	Community interventions and the epidemic prevention potential. Vaccine, 2002, 20, 3254-3262.	1.7	64
92	Semiparametric Methods for Multiple Exposure Mismeasurement and a Bivariate Outcome in HIV Vaccine Trials. Biometrics, 1999, 55, 94-101.	0.8	8
93	A Markov model for measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccines. , 1999, 18, 53-68.		23
94	Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy. , 1998, 17, 185-200.		32
95	Optimal vaccine trial design when estimating vaccine efficacy for susceptibility and infectiousness from multiple populations. , 1998, 17, 1121-1136.		55
96	Semi-parametric models for mismeasured exposure information in vaccine trials. , 1998, 17, 2335-2352.		6
97	A Frailty Mixture Model for Estimating Vaccine Efficacy. Journal of the Royal Statistical Society Series C: Applied Statistics, 1996, 45, 165.	0.5	73
98	Identifying Areas with Elevated Disease Incidence Rates Using Empirical Bayes Estimators. Geographical Analysis, 1996, 28, 187-199.	1.9	36
99	Causal Inference in Infectious Diseases. Epidemiology, 1995, 6, 142-151.	1.2	209
100	Empirical bayes estimators for spatially correlated incidence rates. Environmetrics, 1994, 5, 381-398.	0.6	27
101	Malaria vaccines: lessons from field trials. Cadernos De Saude Publica, 1994, 10, S310-S326.	0.4	13
102	Measuring vaccine efficacy from epidemics of acute infectious agents. Statistics in Medicine, 1993, 12, 249-263.	0.8	36
103	Study Designs for Dependent Happenings. Epidemiology, 1991, 2, 331-338.	1.2	198